Summary:
A double blinded, placebo-controlled, multicenter randomized, phase 3 study to evaluate the efficacy and safety of ORMD-0801 in subjects with type 2 diabetes mellitus with inaequate glycemic control on diet control alone or on diet control and metformin monotherapy.
Qualified Participants Must:
• Be 18-75 years old
•
Have type 2 diabetes with an HbA1c between 7.0 and 9.0%
•
Managing diabetes with diet and excercise alone
•
Or on 1500 mg of Metformin only
•
BMI between 25 and 40
Qualified Participants May Receive:
Compensation for time and travel